Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, today announced the appointment of Timothy Lorber, CPA, as the company's Chief Financial Officer (CFO).

Michael Vander Hoek, the company's existing CFO, who also serves as vice president, Regulatory, will take up the post of vice president, Regulatory position full-time.

Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc, as a managing director and chief accounting officer. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Lorber served as Internal Audit director of Freddie Mac.

'We are extremely excited to be welcoming Tim Lorber to the executive team at Shuttle Pharma,' stated Shuttle Pharma's chairman and CEO, Anatoly Dritschilo, M.D. 'His deep experience, including significant involvement with valuations, M&A transactions, complex financial accounting and Securities Exchange Commission reporting matters will serve the Company well as we advance our mission to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of Radiation Therapy while limiting the late effects of radiation in cancer treatment.'

Lorber will increasingly take up the responsibilities of the role, assuming it full time effective 10 September 2024.

'Michael Vander Hoek has been performing two critical roles for Shuttle for the past four years as both our chief financial officer and our vice president of Regulatory. With the company's growth and the planned initiation of the multi-center Phase 2 clinical trial, Michael will focus his efforts on the successful execution of all regulatory matters, including management of site enrollment, FDA relations, and contract research organization activities to ensure compliance with all matters. I am thankful for Michael's hard work as our chief financial officer during the past four plus years and look forward to his many contributions as we ramp up our clinical activities,' Dr. Dritschilo said.